BWS Financial maintains a 'Buy' on Pharmacyclics (Nasdaq: PCYC), raises price target from $2 to $4.

BWS analyst says, "PCYC ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE